Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3D Medicines Acquires China Rights to Two Immunotherapies in $202 Million Deal

publication date: Dec 10, 2020

3D Medicines of Shanghai acquired greater China rights to two Sellas cancer immunotherapies in an agreement worth up to $202 million. 3DMed will develop and commercialize Sellas' late-stage candidate, galinpepimut-S (GPS), and its next-gen heptavalent immunotherapy, GPS+, currently in preclinical stage. The $202 million includes a $7.5 upfront payment and a $8 million near-term milestone. 3DMed will also pay royalties on sales. Sellas is headquartered in New York City; it acquired rights to GPS from Memorial Sloan Kettering Cancer Center. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital